Publications by authors named "A Yazar"

52 Publications

Treatment of sialorrhea with botulinum toxin A injection in children.

Niger J Clin Pract 2021 Jun;24(6):847-852

Department of Pediatric Pulmonology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey.

Aims: We aimed to evaluate the effectivity and safety of botulinum toxin A (BT-A) to reduce sialorrhea in children with hypersalivation due to neurological diseases.

Methods: Patients who had a complaint of severe sialorrhea were included in the study. Drooling severity of the patients was evaluated using the classification of Thomas-Stonell and Greenberg. The frequency of aspiration before and after the procedure was recorded. The 24-hour saliva amount and mean duration of two consecutive aspirations were recorded. BT-A was injected into the bilateral parotid and submandibular glands by a otorhinolaryngologist under the guidance of ultrasound guidance (USG).

Results: When patients' mean drooling severity scores, drooling frequency scores, mean duration of two consecutive aspirations, and amount of saliva collected before and after procedure were compared, a statistical significance was observed. One-year hospital records before after and injection were examined and it was observed that after BT-A injection, hospital visits were statistically significantly low (P = 0.017).

Conclusion: BT-A injection into salivary glands is well tolerated, is minimally invasive, has low complication rates and should be performed into both parotid and submandibular glands under USG. Although there is still no consensus on the ideal dose and frequency of injections, it is thought that a dose of 1U/kg/gland can be used with safety in pediatric age groups and the dimensions of the salivary glands and quantitative measurements of the amount of saliva should be utilized. Larger studies involving more patients are required in order to constitute a standard injection protocol.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4103/njcp.njcp_85_20DOI Listing
June 2021

Serum B12, homocysteine, and anti-parietal cell antibody levels in children with autism.

Int J Psychiatry Clin Pract 2021 Apr 6:1-6. Epub 2021 Apr 6.

Department of Child Health and Diseases, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey.

Aims: To compare vitamin B12, homocysteine, and anti-parietal cell antibody (APCA) levels between children with ASD and controls, paired in terms of age, sex, and socioeconomic level.

Methods: The research group consisted of 69 children, 36 with ASD and 33 controls. The severity of ASD was determined using the Childhood Autism Rating Scale (CARS). Serum vitamin B12, homocysteine and human anti-parietal cell levels were analysed using enzyme-linked immunosorbent assay.

Results: The serum vitamin B12 and homocysteine levels in children with ASD were lower than in the control group, but there was no significant difference in terms of APCA levels.

Conclusions: Deficiencies in micronutrients, such as B12, may play a role in the pathogenesis and clinical symptoms of autism. However, it is believed that these parameters should be analysed in a wider population to clarify their effect on the aetiology of ASD.KEY POINTWe hypothesised that low levels of vitamin B12 and homocysteine levels reported in previous studies might be associated with APCA levels.The homocysteine and B12 levels were found to be significantly lower in children with ASD. There was no significant difference in serum APCA levels.No significant relationship was found between B12 levels and APCA.Given all these findings, it can be stated that vitamin B12 deficiency is not associated with an absorption-related mechanism due to the presence of APCA.Deficiencies in micronutrients, such as B12, may play a role in the pathogenesis and clinical symptoms of autism.In future studies, it will be beneficial to investigate other mechanisms that may cause vitamin B12 deficiency.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/13651501.2021.1906906DOI Listing
April 2021

Paediatric systemic lupus erythematosus: A single referral centre experience.

J Pak Med Assoc 2021 Jan;71(1(A)):136-139

Department of Pediatrics, Necmettin Erbakan University, Konya, Turkey.

In this study, the clinical and laboratory findings, management and follow-up of 32 children with paediatric systemic lupus erythematosus (pSLE) were evaluated to determine the prognostic factors in pSLE. Of the 32 patients, 25 (78.1%) were females. Age at onset of symptoms and diagnosis in the patients were 147.6 ± 49 months and 154.3 ± 48 months, respectively. The most common symptom on admission were joint problems, seen in 25 (78.1%) patients. Haematological alterations were seen in 25 (78.1%) cases during follow-up. Lupus nephritis was diagnosed in 10 (31.2%) patients. Malar rash was seen in a total of 12 (37.5%) patients during follow up, however it had been noted in five (15.6%) patients on admission. Antinuclear antibody and anti-dsDNA were positive in all patients and 31 (96.8%) patients, respectively. Decreased complement 3 and 4 levels were noted in 23 (71.8%) patients. Antiphospholipid antibody was studied in 27 patients and it was found to be positive in 13 (48.1%) patients. In conclusion, based on our findings, we would like to emphasize that pSLE has a large and remarkable clinical and laboratory findings.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5455/JPMA.61641DOI Listing
January 2021

Early Kidney Injury in Immunoglobulin A Vasculitis: Role of Renal Biomarkers.

Pediatr Int 2021 Jan 10. Epub 2021 Jan 10.

Department of Pediatric Nephrology, Meram Medical Faculty, Necmettin Erbakan University, Turkey.

Background: We aimed to determine whether urine Kidney Injury Molecule-1 (KIM-1) and Neutrophil Gelatinase Associated Lipocalin (NGAL) can be used as early noninvasive biomarkers of kidney injury in Immunoglobulin A vasculitis.

Methods: Patients who were diagnosed with Immunoglobulin A vasculitis were included in the study. Urine samples were collected for determination of urine KIM-1and NGAL levels. The control group was comprised of age-matched healthy children.

Results: 61 patients who diagnosed with Immunoglobulin A vasculitis were included in the study. 37.7% of these patients were determined to have renal involvement. Median KIM-1 was found to be statistically significantly higher in the patient group (69.59 pg/ml) compared to the control group (40.84 pg/ml) (p= 0.001). Median NGAL was determined to be statistically significantly higher in the patient group (59.87 ng/ml) compared to the control group (44.87 ng/ml) (p=0.013). In 23.6% of the patients without renal involvement at admission were found to develop renal involvement within following six months. When median KIM-1 and NGAL at admission of these patients were compared with the control group, they were determined to be statistically significantly higher (p= 0.001, p= 0.003).

Conclusions: The fact that our patients with late-term nephropathy had no hematuria and/or proteinuria and that KIM-1and NGAL levels, however, were determined to be high indicates that these biomarkers might be potentially reliable, noninvasive and early determinants of kidney injury.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ped.14600DOI Listing
January 2021

Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy.

J Oncol 2020 29;2020:1360431. Epub 2020 Jun 29.

Department of Internal Diseases, School of Medicine, Acibadem University, Istanbul, Turkey.

Expression of -glycolyl GM3 (NeuGcGM3) ganglioside was detected in the tumor specimens of patients who were on Racotumomab anti-idiotype vaccine maintenance treatment, and prognostic significance as a biomarker was investigated. No statistically significant association was observed in the multivariate analysis between overall survival and tissue NeuGcGM3 IHC levels. Although numerically there was a difference favoring less intense IHC for better prognosis, this did not reach statistical power. However, there was a strong correlation between Racotumomab doses and overall survival (OS). Mean OS of the patient with more than 10 Racotumomab application was significantly longer than the patient who had less than 10 injections (70.7 months vs. 31.1 months, < 0.001). We propose that, regardless of staining intensity, the presence of NeuGcGM3 in patient tissues might be an indicator of benefit in Racotumomab treatment.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/1360431DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341415PMC
June 2020
-->